Abstract
TWe aimed to determine whether the excision repair cross-complementation group 1 (ERCC1) expression predicts response to cisplatin-based chemotherapy in patients with small cell lung cancer (SCLC). This was a retrospective study, in which hospital files of 31 patients (29 males, 2 females; mean age, 62.26±7.71 years) were reviewed. All patients were treated with etoposide+cisplatin. The lung biopsy and mediastinal lymph node samples were applied anti-human monoclonal antibodies against ERCC1: immunohistochemical staining was considered positive if 25-100% of the cells showed nuclear staining, and negative if less than 25% of the cells showed negative or slight staining. Response to treatment was evaluated as regression (complete or partial response), progressive disease, or stable disease.
Highlights
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death around the world [1,2]
We aimed to determine whether the excision repair cross-complementation group 1 (ERCC1) expression predicts response to cisplatinbased chemotherapy in patients with small cell lung cancer (SCLC)
High expression of ERCC1 was associated with higher response rate to cisplatin-based regimens in patients with SCLC
Summary
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death around the world [1,2]. It is divided into two broad categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is highly malignant and an aggressive type of lung cancer [3,4]. Five-year survival for patients with SCLC is only 5-10% [5]. While five-year survival up to 14% has been reported for patients with limited-stage disease,
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
